Goto content

Leishrisk, Bridging Research and Leishmanianis Control

Leishrisk, Bridging Research and Leishmanianis Control

LeishRisk workshop - Programme: Day 1

<-- back to Workshop Programme

Day 1     Day 2     Day 3

Day 1, Monday 12 November 2007

Introduction (Jean-Claude Dujardin & David Hendrickx)
Pre-screening of new documentary, produced by Jorge Alvar (WHO)
Coffee break

Session 1: Methods (chaired by M. Miles & E. Cupolillo)
This session will consider methods for: diagnosis and treatment, molecular epidemiology, and vector control. Drug resistance will be considered as part of the session on treatment failure and drug resistance.
-         Diagnosis (Suman Rijal, B.P. Koirala Institute of Health Sciences, Nepal)
-         Molecular epidemiology (Gabriel Schoenian, Charite Universitätsmedizin Berlin, Germany)
-         Treatment (Gustavo Romero, Núcleo de Medicina Tropical, Universidade de Brasilia, Brasil)
-         Vector control (Michele Maroli, Istituto Superiore di Sanità, Italy)
Lunch Break

Session 2. Environmental changes (P. Ready & Z. Abdeen)
In this session we will consider how environmental changes might affect the maintenance or spread of leishmaniasis, either directly through parasite survival and development in hosts or indirectly through modifications of transmission cycles resulting from climate, other environmental or social changes. In this way, the presentations will promote discussions among those of different biomedical disciplines.  
-         Domestication of transmission cycles in Latin America (Ana Lineth Garcia, Universidad Mayor de San Simon Facultad de Medicina, Bolivia)
-         Changes in climate, land use and social behaviour and the emergence of leishmaniasis in Eurasia and Africa (Paul Ready, Natural History Museum, UK )
-         Emergence of leishmaniasis in northern Italy since 1990 (Marina Gramiccia, Istituto Superiore di Sanità, Italy)
-         ECDC and vector-borne diseases (Evelyn Depoortere, European Centre of Disease Prevention and Control, Sweden)

Coffee break
Session 3. Treatment failure and drug resistance (S. Sundar & S. Croft)
Treatment failure can be due to decreased drug sensitivity of Leishmania species (intrinsic or acquired resistance), the immune status of the patient, the pharmacokinetic properties of the drug or the quality of the drug and patient care. This session will explore the contribution of parasite and host factors to treatment failure and discuss approaches to identify the reasons for this failure.
-         Clinical failure, resistance and combinations (Shyam Sundar, Banadaras university, India)
-         Host factors related with treatment failure (Syamal Roy, Indian Institute of Chemical Biology, India)
-         Clinical response, species variation and intrinsic resistance (Byron Arana, Universidad Del Valle, Guatemala)
-         Antimonial treatment failure in anthroponotic visceral leishmaniasis: towards improved tools and strategies for epidemiological surveillance and disease control (Saskia Decuypere, Strathclyde Institute of Pharmacy & Biomedical Sciences, Scotland and ITM-A, Belgium)
Introduction of the E-compendium (Jorge Alvar and Jason Pickering, WHO)
Reception and walking dinner at the ITM-A



LeishRisk supports the initiative to develop a VL Diagnostics Quality Assurance Network.  

Download a report of the first consultation meeting <here>